Ingo A Eland
St. Antonius Hospital,
Po Box. 2500, 3430 EM, Nieuwegein
England
Research Article
Insulin Glargine versus Insulin Detemir: Glycemic Control and Insulin Dose in Type 2 Diabetes Mellitus Patients Using a Medical Record Linkage System in the Netherlands
Author(s): Ingo A Eland, Edith M. Heintjes, Leanne Houweling, Ricardo deGrooth, Thiemo F. Veneman and K. Paul BouterIngo A Eland, Edith M. Heintjes, Leanne Houweling, Ricardo deGrooth, Thiemo F. Veneman and K. Paul Bouter
Background: In randomized controlled trials, patients with type 2 diabetes mellitus required higher doses of insulin detemir than insulin glargine to obtain the same glycemic control. However, this may differ in daily clinical practice.
Methods: We conducted a cohort study to compare glycemic control, daily basal insulin dose and persistence in The Netherlands. Data were obtained from the PHARMO record linkage system. Patients starting glargine or detemir in 2004 through 2007 were included if they had a follow-up and history of at least 1 year, including glycated hemoglobin (HbA1c) measurements. Glycemic control and insulin dose were compared within 1 year after start of treatment. Average insulin dose was calculated based on the amount of insulin dispensed overtime.
Results: A total of 708 patients on glargine and.. View More»
